TY - JOUR
T1 - Cardiovascular safety of acute recombinant human thyrotropin administration to patients monitored for differentiated thyroid cancer
AU - Biondi, Bernadette
AU - Palmieri, Emiliano A.
AU - Pagano, Loredana
AU - Klain, Michele
AU - Scherillo, Giovanna
AU - Salvatore, Marco
AU - Fenzi, Gianfranco
AU - Lombardi, Gaetano
AU - Fazio, Serafino
PY - 2003/1/1
Y1 - 2003/1/1
N2 - Eleven patients who had undergone total thyroidectomy for differentiated thyroid cancer and who were on chronic TSH-suppressive therapy with levothyroxine (L-T4), underwent 24-h Holter electrocardiogram and Doppler-echocardiography before and after acute recombinant human TSH (rhTSH) administration for disease staging. The treatment, which was generally well tolerated, did not affect circulating thyroid hormones levels, nor did it have measurable effects on heart rate, rhythm, left ventricular morphology, or systo-diastolic function. Notably, arterial blood pressure tended to be slightly reduced after rhTSH administration, although in no instance did the patients become frankly symptomatic. Our data demonstrate that rhTSH does not alter cardiovascular function acutely. Consequently, it can safely be used in the routine staging of patients affected by differentiated thyroid cancer.
AB - Eleven patients who had undergone total thyroidectomy for differentiated thyroid cancer and who were on chronic TSH-suppressive therapy with levothyroxine (L-T4), underwent 24-h Holter electrocardiogram and Doppler-echocardiography before and after acute recombinant human TSH (rhTSH) administration for disease staging. The treatment, which was generally well tolerated, did not affect circulating thyroid hormones levels, nor did it have measurable effects on heart rate, rhythm, left ventricular morphology, or systo-diastolic function. Notably, arterial blood pressure tended to be slightly reduced after rhTSH administration, although in no instance did the patients become frankly symptomatic. Our data demonstrate that rhTSH does not alter cardiovascular function acutely. Consequently, it can safely be used in the routine staging of patients affected by differentiated thyroid cancer.
UR - http://www.scopus.com/inward/record.url?scp=0037242834&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037242834&partnerID=8YFLogxK
U2 - 10.1210/jc.2002-020544
DO - 10.1210/jc.2002-020544
M3 - Article
C2 - 12519854
AN - SCOPUS:0037242834
VL - 88
SP - 211
EP - 214
JO - Journal of Clinical Endocrinology and Metabolism
JF - Journal of Clinical Endocrinology and Metabolism
SN - 0021-972X
IS - 1
ER -